Mesenchymal Chondrosarcoma: Clinicopathologic Study of 20 Cases
Authors:
- Rachel J. ShakkedRachel J. Shakked
- David S. GellerDavid S. Geller
- Richard GorlickRichard Gorlick
- Howard D. DorfmanHDHoward D. Dorfman
- 1 January 2012
- journal article
- case report
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 136 (1) , 61-75
Abstract
Context .—Mesenchymal chondrosarcoma is a rare, high-grade malignancy of bone or soft tissue with a unique, biphasic histology and poor prognosis. Because of its rarity and variable length of disease-free survival, the natural history of the disease remains poorly understood. Objective .—To present clinical, radiographic, and histopathologic features of mesenchymal chondrosarcoma from one of the largest case series collected by a single, senior-level bone pathologist. Design .—Twenty cases were reviewed in consultations spanning 45 years. Results .—Eighteen tumors (90%) originated in bone, and 2 tumors (10%) were of extraskeletal origin. Of the skeletal tumors, locations included craniofacial bones (n = 9; 50%), ribs and chest wall (n = 4; 22%), sacrum and spinal elements (n = 3; 17%), and lower extremities (n = 2; 11%), whereas soft tissue tumors were located about the scapula (n = 1; 50%) and lower extremity (n = 1; 50%). Plain radiographs demonstrated calcified, osteolytic lesions with extraosseous extension. Typical histologic features were identified consisting of small, round or spindled cells, interspersed with hyaline cartilage islands. Seventeen patients (85%) were treated surgically, and 8 patients (40%) received adjuvant treatment. Seven patients (35%) were living at last follow-up, 1.8 to 12.5 years after diagnosis, and 8 patients (40%) died between 1.2 and 21.8 years after diagnosis. Conclusions .—Mesenchymal chondrosarcoma presents multiple challenges. Diagnostic pitfalls include inadequate biopsy samples, which may result in sample error. Sox9 has been proposed as a unique marker for mesenchymal chondrosarcoma which may improve diagnostic specificity. Treatment and prognosis vary considerably. Patients who receive surgery and chemotherapy seem to fare better. Multicenter studies with higher sample numbers may improve our understanding of this malignancy.Keywords
This publication has 42 references indexed in Scilit:
- Primary mesenchymal chondrosarcoma of the breastIndian Journal of Pathology and Microbiology, 2009
- Efficacy of Weekly Docetaxel and Bevacizumab in Mesenchymal Chondrosarcoma: A New Theranostic Method Combining Xenografted Biopsies with a Mathematical ModelCancer Research, 2008
- Oncogenes and CancerNew England Journal of Medicine, 2008
- Congenital mesenchymal chondrosarcoma of the orbitOphthalmology, 2004
- MESENCHYMAL CHONDROSARCOMA OF THE KIDNEYJournal of Urology, 2001
- Mesenchymal chondrosarcoma: A clinicopathologic and flow cytometric study of 13 cases presenting in the central nervous systemCancer, 1996
- Mesenchymal chondrosarcoma of the pleuraEuropean Respiratory Journal, 1996
- t(4;19)(q35;q13.1): A recurrent change in primitive mesenchymal tumors?Cancer Genetics and Cytogenetics, 1996
- Mesenchymal chondrosarcoma A cytogenetic, immunohistochemical and ultrastructural studyCancer Genetics and Cytogenetics, 1995
- Chromosomal rearrangements in chondromatous tumorsCancer, 1990